Medroxyprogesterone acetate in non‐metastatic gestational trophoblastic disease

GARY L. GOLDBERG, KOBUS CLOETE, BASIL BLOCH, KLAUS WISWEDEL, MARCO M. ALTARAS

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Summary. The effect of medroxyprogesterone acetate (MPA: Depo‐Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non‐metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non‐hormonal methods of contraception. In the whole group of 84 patients 18 (21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA (9/45) and the oral contraceptive group (2/13) and MPA and the non‐hormonal contraceptive groups (7/26).

Original languageEnglish (US)
Pages (from-to)22-25
Number of pages4
JournalBJOG: An International Journal of Obstetrics & Gynaecology
Volume94
Issue number1
DOIs
StatePublished - Jan 1987

    Fingerprint

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this